Coronavirus, Paul-Ehrlich-Institut grants BioNTech approval for clinical vaccine testing

Apr 22, 2020

The following photos have been selected for you by the IMAGO picture desk on this topic. For more pictures please use the search function.

22 04 2020, xmkx, Coronavirus, Paul Ehrlich Institute Federal Institute for Vaccines and Biomedical Drugs, Langen Hessen Germany DE Paul Ehrlich Institute
22 04 2020, xmkx, Coronavirus, Paul Ehrlich Institute Federal Institute for Vaccines and Biomedical Drugs, Langen Hessen Germany DE Paul Ehrlich Institute
22 04 2020, xmkx, Coronavirus, Paul Ehrlich Institute Federal Institute for Vaccines and Biomedical Drugs, Langen Hessen Germany DE Paul Ehrlich Institute
22 04 2020, xmkx, Coronavirus, Paul Ehrlich Institute Federal Institute for Vaccines and Biomedical Drugs, Langen Hessen Germany DE Paul Ehrlich Institute
Mainz, An der Goldgrube , 26 03 2020, The companys activities focus on the development and manufacture of technologies and drugs for individualized cancer immunotherapy BioNTech SE is stepping up its global fight against the coronavirus and reports rapid progress in the development of a vaccine Mainz An der Goldgrube Rheinland Pfalz Germany
Mainz, An der Goldgrube , 26 03 2020, The companys activities focus on the development and manufacture of technologies and drugs for individualized cancer immunotherapy BioNTech SE is stepping up its global fight against the coronavirus and reports rapid progress in the development of a vaccine Mainz An der Goldgrube Rheinland Pfalz Germany
Mainz, An der Goldgrube , 26 03 2020, The companys activities focus on the development and manufacture of technologies and drugs for individualized cancer immunotherapy BioNTech SE is stepping up its global fight against the coronavirus and reports rapid progress in the development of a vaccine Mainz An der Goldgrube Rheinland Pfalz Germany
Feature Biontech 17 03 2020, Mainz Biontech, the Mainz-based specialist for immune therapies, is stepping up its global fight against the corona virus and reports rapid progress in the development of a vaccine. In the meantime, around 7000 people in Germany have contracted the virus.
Feature Biontech 17 03 2020, Mainz Biontech, the Mainz-based specialist for immune therapies, is stepping up its global fight against the corona virus and reports rapid progress in the development of a vaccine. Meanwhile, around 7000 people in Germany have fallen ill with the virus. Company headquarters in Mainz, logos, brands, lettering, flags with lettering Mainz Rheinland Pfalz Germany
Feature Biontech 17 03 2020, Mainz Biontech, the Mainz-based specialist for immune therapies, is stepping up its global fight against the corona virus and reports rapid progress in the development of a vaccine. In the meantime, around 7000 people in Germany have contracted the virus.
Feature Biontech 17 03 2020, Mainz Biontech, the Mainz-based specialist for immune therapies, is stepping up its global fight against the corona virus and reports rapid progress in the development of a vaccine. Meanwhile, around 7000 people in Germany have fallen ill with the virus. Company headquarters in Mainz, logos, brands, lettering, flags with lettering Mainz Rheinland Pfalz Germany
09 03 2020, Berlin, Germany Joint press conference on coronavirus research Federal Research Minister Anja Karliczek and Federal Health Minister Jens Spahn present the activities of the Federal Government Photo Prof Klaus Cichutek, President of the Paul Ehrlich Institute